Listing of the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A ~~compounds~~ compound of formula I:



I

wherein:

R^1 is selected from:

1) H, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{3-6} cycloalkyl, and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
   a) C_{1-6} alkyl,
   b) C_{3-6} cycloalkyl,
   c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   f) $(F)_pC_{1-3}$ alkyl,
   g) halogen,
   h) OR^4,
   i) $O(CH_2)_s OR^4$,

j) CO_2R^4,

k) $(CO)NR^{10}R^{11}$,

l) $O(CO)NR^{10}R^{11}$,

m) $N(R^4)(CO)NR^{10}R^{11}$,

n) $N(R^{10})(CO)R^{11}$,

o) $N(R^{10})(CO)OR^{11}$,

p) $SO_2NR^{10}R^{11}$,

q) $N(R^{10})\ SO_2R^{11}$,

r) $S(O)_mR^{10}$,

s) CN,

t) $NR^{10}R^{11}$,

u) $N(R^{10})(CO)NR^4R^{11}$, and

v) $O(CO)R^4$; and

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:

a) $C_{1\text{-}6}$ alkyl,

b) $C_{3\text{-}6}$ cycloalkyl,

c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

f) $(F)_pC_{1\text{-}3}$ alkyl,

g) halogen,

h) OR^4,

i) $O(CH2)_sOR^4$,

j) CO_2R^4,

k) $(CO)NR^{10}R^{11}$,

l) $O(CO)NR^{10}R^{11}$,

m) $N(R^4)(CO)NR^{10}R^{11}$,

n) $N(R^{10})(CO)R^{11}$,

o) $N(R^{10})(CO)OR^{11}$,

p) $SO_2NR^{10}R^{11}$,
q) $N(R^{10})\ SO_2R^{11}$,
r) $S(O)_mR^{10}$,
s) CN,
t) $NR^{10}R^{11}$,
u) $N(R^{10})(CO)NR^4R^{11}$, and
v) $O(CO)R^4$; and

R^2 is independently selected from H and:

1) $C_{1\text{-}6}$ alkyl,
2) $C_{3\text{-}6}$ cycloalkyl,
3) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
4) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
5) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
6) $(F)_pC_{1\text{-}3}$ alkyl,
7) halogen,
8) OR^4,
9) $O(CH_2)_sOR^4$,
10) CO_2R^4,
11) $(CO)NR^{10}R^{11}$,
12) $O(CO)NR^{10}R^{11}$,
13) $N(R^4)(CO)NR^{10}R^{11}$,
14) $N(R^{10})(CO)R^{11}$,
15) $N(R^{10})(CO)OR^{11}$,
16) $SO_2NR^{10}R^{11}$,
17) $N(R^{10})\ SO_2R^{11}$,
18) $S(O)_mR^{10}$,
19) CN,
20) $NR^{10}R^{11}$,
21) $N(R^{10})(CO)NR^4R^{11}$, and

22) $O(CO)R^4$;

R^7 is selected from:

1) H, C_0-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_{3-6} cycloalkyl and heterocycle, unsubstituted or substituted with one or more substituents independently selected from:
   a) C_{1-6} alkyl,
   b) C_{3-6} cycloalkyl,
   c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
   f) $(F)_pC_{1-3}$ alkyl,
   g) halogen,
   h) OR^4,
   i) $O(CH_2)_sOR^4$,
   j) CO_2R^4,
   k) $(CO)NR^{10}R^{11}$,
   l) $O(CO)NR^{10}R^{11}$,
   m) $N(R^4)(CO)NR^{10}R^{11}$,
   n) $N(R^{10})(CO)R^{11}$,
   o) $N(R^{10})(CO)OR^{11}$,
   p) $SO_2NR^{10}R^{11}$,
   q) $N(R^{10})\ SO_2R^{11}$,
   r) $S(O)_mR^{10}$,
   s) CN,
   t) $NR^{10}R^{11}$,
   u) $N(R^{10})(CO)NR^4R^{11}$,
   v) $O(CO)R^4$; and

2) aryl or heteroaryl, unsubstituted or substituted with one or more substituents independently selected from:

a) C_{1-6} alkyl,

b) C_{3-6} cycloalkyl,

c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,

f) $(F)_pC_{1-3}$ alkyl,

g) halogen,

h) OR^4,

i) $O(CH_2)_sOR^4$,

j) CO_2R^4,

k) $(CO)NR^{10}R^{11}$,

l) $O(CO)NR^{10}R^{11}$,

m) $N(R^4)(CO)NR^{10}R^{11}$,

n) $N(R^{10})(CO)R^{11}$,

o) $N(R^{10})(CO)OR^{11}$,

p) $SO_2NR^{10}R^{11}$,

q) $N(R^{10})\ SO_2R^{11}$,

r) $S(O)_mR^{10}$,

s) CN,

t) $NR^{10}R^{11}$,

u) $N(R^{10})(CO)NR^4R^{11}$, and

v) $O(CO)R^4$;

R^4 is selected from: H, C_{1-6} alkyl, $(F)_pC_{1-6}$ alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_1-C_6 alkoxy;

R^5 is independently selected from H, substituted or unsubstituted C_1-C_6 alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl, OR^4, $N(R^4)_2$, CO_2R^4 and $(F)_pC_{1-6}$ alkyl;

W is O, NR^4 or $C(R^4)_2$;

X is C or S;

Y is O, $(R^4)_2$, NCN, NSO_2CH_3 or $NCONH_2$, or Y is O_2 when X is S;

R^3 is independently selected from H, substituted or unsubstituted C_1-C_3 alkyl, CN and CO_2R^4;

R^6 is independently selected from H and:

a) C_{1-6} alkyl,
b) C_{3-6} cycloalkyl,
c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
d) heteroaryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
e) heterocycle, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4,
f) $(F)_pC_{1-3}$ alkyl,
g) halogen,
h) OR^4,
i) $O(CH_2)_sOR^4$,
j) CO_2R^4,
k) $(CO)NR^{10}R^{11}$,
l) $O(CO)NR^{10}R^{11}$,
m) $N(R^4)(CO)NR^{10}R^{11}$,
n) $N(R^{10})(CO)R^{11}$,
o) $N(R^{10})(CO)OR^{11}$,
p) $SO_2NR^{10}R^{11}$,
q) $N(R^{10})\ SO_2R^{11}$,
r) $S(O)_mR^{10}$,
s) CN,
t) $NR^{10}R^{11}$,
u) $N(R^{10})(CO)NR^4R^{11}$, and
v) $O(CO)R^4$;

R^{10} and R^{11} are independently selected from: H, C_{1-6} alkyl, $(F)_pC_{1-6}$ alkyl, C_{3-6} cycloalkyl, aryl, heteroaryl and benzyl, unsubstituted or substituted with halogen, hydroxy or C_1-C_6 alkoxy, where R^{10} and R^{11} may be joined together to form a ring selected from: azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R^4;

G-J is selected from: N, N–$C(R^5)_2$, C=$C(R^5)$, C=N; $C(R^5)$, $C(R^5)$-$C(R^5)_2$, $C(R^5)$-$C(R^5)_2$-$C(R^5)_2$, C=$C(R^5)$-$C(R^5)_2$, $C(R^5)$-$C(R^5)$=$C(R^5)$, $C(R^5)$-$C(R^5)_2$-$N(R^5)$, C=$C(R^5)$-$N(R^5)$, $C(R^5)$-$C(R^5)$=N, $C(R^5)$-$N(R^5)$-$C(R^5)_2$, C=N-$C(R^5)_2$, $C(R^5)$-N=$C(R^5)$, $C(R^5)$-$N(R^5)$-$N(R^5)$, C=N-$N(R^5)$, N-$C(R^5)_2$-$C(R^5)_2$, N-$C(R^5)$=$C(R^5)$, N-$C(R^5)_2$-$N(R^5)$, N-$C(R^5)$=N, N-$N(R^5)$-$C(R^5)_2$ and N-N=$C(R^5)$;

Q, T, U and V are each independently a carbon atom or a nitrogen atom wherein at least one but no more than three of Q, T, U and V are nitrogen atoms, and wherein when any of Q, T, U, or V is a carbon atom it is unsubstituted or substituted where the substituents are independently selected from R^6;

p is	0 to 2q+1, for a substituent with q carbons;
m is	0, 1 or 2;
n is	0 or 1;
s is	1, 2 or 3;

"heterocyclic" is a stable 5- to 7- membered monocyclic- or stable 8- to 11- membered bicyclic heterocyclic ring system, which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quarternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring;

"heteroaryl" is a stable 5- to 7- membered monoclcyclic stable 9- to 10-membered fused bicyclic heterocyclic ring system which contains an aromatic ring, any ring of which may be saturated;

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

2. (Currently Amended) The compound of claim 1 of the formula Ia:



~~and~~ or a pharmaceutically acceptable salts ~~and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

3. (Currently Amended) The compound of claim 2, wherein R^7 is phenyl, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,
b) OH,
c) OR^5,
d) halogen,
e) CO_2R^4,
f) $S(O)_mR^5$,
g) $N(R^4)_2$, and
j) CN,

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

4. (Currently Amended) The compound of claim 2, wherein R^7 is heteroaryl, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,
b) OH,
c) OR^5,
d) halogen,
e) CO_2R^4,
f) $S(O)_mR^5$,

g) $N(R^4)_2$, and

j) CN,

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

5. (Currently Amended) The compound of claim 2, wherein R^7 is selected from H and C_1-C_6 alkyl, C_1-C_6 alkenyl, C_1-C_6 alkynyl, C_3-C_6 cycloalkyl, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,

b) C_{1-6} alkoxy,

c) fluorine,

d) HO,

e) OR^5,

f) CO_2R^4,

g) $CON(R^4)_2$,

h) $S(O)_mR^5$, and

i) $N(R^4)_2$; and

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

6. (Currently Amended) The compound of claim 2, wherein R^7 is heterocycle, unsubstituted or substituted with one or substituents independently selected from:

a) C_{1-6} alkyl,

b) C_{1-6} alkoxy,

c) fluorine,

d) HO,

e) OR^5,

f) CO_2R^4,

g) $CON(R^4)_2$,

h) $S(O)_mR^5$, and

i) $N(R^4)_2$; and

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

7. (Currently Amended) The compound of claim 1 of the formula Ib:



Ib

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

8. (Currently Amended) The compound of claim 1 of the formula Ic:



Ic

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

9. (Currently Amended) The compound of claim 1 of the formula Id:



Id

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

10. (Currently Amended) A compound selected from:















,



,



,



,

~~and~~ or a pharmaceutically acceptable ~~salts and~~ salt or individual ~~diastereomers~~ diastereomer thereof.

11. (Original) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 1.

12. (Canceled)

13. (Currently Amended) A method for treating~~, controlling, ameliorating or reducing the risk of~~ headache~~, migraine or cluster headache~~ in a mammalian patient in need of such which comprises administering to the patient a therapeutically effective amount of the compound of Claim 1.

14 -57. (Canceled)

58. (New) The method of claim 13 wherein the headache is a migraine headache or cluster headache.